Ron D. Jachimowicz

1.1k total citations
17 papers, 319 citations indexed

About

Ron D. Jachimowicz is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Ron D. Jachimowicz has authored 17 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Ron D. Jachimowicz's work include DNA Repair Mechanisms (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immune Cell Function and Interaction (3 papers). Ron D. Jachimowicz is often cited by papers focused on DNA Repair Mechanisms (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immune Cell Function and Interaction (3 papers). Ron D. Jachimowicz collaborates with scholars based in Germany, United States and Israel. Ron D. Jachimowicz's co-authors include Hans Christian Reinhardt, Andreas Engert, Elke Pogge von Strandmann, Katrin S. Reiners, Achim Rothe, Maike Sauer, Sven Borchmann, Annette Plütschow, Lukas C. Heukamp and Michael Hallek and has published in prestigious journals such as Blood, Scientific Reports and International Journal of Cancer.

In The Last Decade

Ron D. Jachimowicz

15 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron D. Jachimowicz Germany 10 161 130 104 97 32 17 319
Christophe Le Clorennec France 11 246 1.5× 119 0.9× 171 1.6× 89 0.9× 47 1.5× 17 392
Sylvia Snauwaert Belgium 10 182 1.1× 108 0.8× 85 0.8× 129 1.3× 22 0.7× 34 324
Federica Melle Italy 8 131 0.8× 63 0.5× 89 0.9× 138 1.4× 33 1.0× 18 285
Athalia R. Pyzer United States 9 183 1.1× 200 1.5× 156 1.5× 56 0.6× 63 2.0× 23 398
Mahan Moshir Belgium 6 99 0.6× 95 0.7× 65 0.6× 34 0.4× 21 0.7× 11 192
Rinat Eshel Israel 9 147 0.9× 87 0.7× 119 1.1× 21 0.2× 33 1.0× 19 325
Jing Christine Ye United States 7 139 0.9× 61 0.5× 89 0.9× 35 0.4× 30 0.9× 20 262
Nicole Adrian Germany 8 323 2.0× 131 1.0× 85 0.8× 192 2.0× 23 0.7× 10 428
Taku Tsukamoto Japan 10 116 0.7× 44 0.3× 162 1.6× 83 0.9× 32 1.0× 50 304

Countries citing papers authored by Ron D. Jachimowicz

Since Specialization
Citations

This map shows the geographic impact of Ron D. Jachimowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron D. Jachimowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron D. Jachimowicz more than expected).

Fields of papers citing papers by Ron D. Jachimowicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron D. Jachimowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron D. Jachimowicz. The network helps show where Ron D. Jachimowicz may publish in the future.

Co-authorship network of co-authors of Ron D. Jachimowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Ron D. Jachimowicz. A scholar is included among the top collaborators of Ron D. Jachimowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron D. Jachimowicz. Ron D. Jachimowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Jachimowicz, Ron D., et al.. (2024). Starvation-induced metabolic rewiring affects mTORC1 composition in vivo. Scientific Reports. 14(1). 28296–28296.
3.
Tresckow, Bastian von, et al.. (2023). Mouse models of diffuse large B cell lymphoma. Frontiers in Immunology. 14. 1313371–1313371. 1 indexed citations
4.
Wagener, Rabea, Anke K. Bergmann, Stephanie Panier, et al.. (2023). Optical genome mapping identifies structural variants in potentially new cancer predisposition candidate genes in pediatric cancer patients. International Journal of Cancer. 154(4). 607–614. 3 indexed citations
5.
Sprute, Rosanne, et al.. (2022). Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection. 50(5). 1399–1404. 18 indexed citations
6.
Kobayashi, Yuta, Matías A. Bustos, Yoshiaki Shoji, et al.. (2022). Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor. Cells. 11(20). 3311–3311. 2 indexed citations
7.
Murakami, Tomohiro, Yoshiaki Shoji, Tomohiko Nishi, et al.. (2021). Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Molecular Oncology. 15(4). 1069–1087. 16 indexed citations
8.
Bröckelmann, Paul J., et al.. (2020). Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. Cells. 9(10). 2287–2287. 19 indexed citations
9.
10.
Jachimowicz, Ron D., et al.. (2019). DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle. 18(13). 1423–1434. 22 indexed citations
11.
Jachimowicz, Ron D. & Hans Christian Reinhardt. (2019). UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. Molecular & Cellular Oncology. 6(2). 1–3. 7 indexed citations
12.
Dietlein, Felix, Lisa Thelen, Mladen Jokić, et al.. (2014). A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC. Cancer Discovery. 4(5). 592–605. 53 indexed citations
13.
Jachimowicz, Ron D. & Andreas Engert. (2014). The Challenging Aspects of Managing Adolescents and Young Adults with Hodgkin's Lymphoma. Acta Haematologica. 132(3-4). 274–278. 9 indexed citations
14.
Jachimowicz, Ron D., Sven Borchmann, & Achim Rothe. (2014). Multi-Specific Antibodies for Cancer Immunotherapy. BioDrugs. 28(4). 331–343. 17 indexed citations
15.
Rothe, Achim, Ron D. Jachimowicz, Sven Borchmann, et al.. (2013). The bispecific immunoligand ULBP2‐aCEA redirects natural killer cells to tumor cells and reveals potent anti‐tumor activity against colon carcinoma. International Journal of Cancer. 134(12). 2829–2840. 51 indexed citations
16.
Sauer, Maike, Annette Plütschow, Ron D. Jachimowicz, et al.. (2012). Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. American Journal of Hematology. 88(2). 113–115. 56 indexed citations
17.
Jachimowicz, Ron D., Giulio Fracasso, Paul J. Yazaki, et al.. (2011). Induction ofIn VitroandIn VivoNK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma. Molecular Cancer Therapeutics. 10(6). 1036–1045. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Le Clorennec Breakdown of academic impact, for papers by Sylvia Snauwaert Breakdown of academic impact, for papers by Federica Melle Breakdown of academic impact, for papers by Athalia R. Pyzer Breakdown of academic impact, for papers by Mahan Moshir Breakdown of academic impact, for papers by Rinat Eshel Breakdown of academic impact, for papers by Jing Christine Ye Breakdown of academic impact, for papers by Nicole Adrian Breakdown of academic impact, for papers by Taku Tsukamoto
Rankless by CCL
2026